Red Flags Detected
- Material Weakness (new) — Company acknowledges potential for material weaknesses in internal controls over financial reporting, though none currently identified.
Avalyn Pharma raises $316M in May IPO; Q1 loss widens 54% to $27M on clinical acceleration
Filed June 3, 2026 · Period ending March 31, 2026 · ~1 min read
Key Changes
-
high
IPO completed May 1, 2026 raised $316M net; combined with $123M cash at March 31 and $15M term loan draw, company projects runway into 2029 to advance lead candidates AP01 (Phase 2b) and AP02 (Phase 2).
MD&A: IPO and Cash Runway verify on EDGAR → -
high
Q1 2026 net loss $26.9M, up 54% from $17.5M in Q1 2025; R&D spending jumped 50% to $22.9M driven by $2.2M increase in AP01 costs and $4.0M increase in AP02 trial spending.
MD&A: Financial Results verify on EDGAR → -
high
Operating cash burn accelerated to $29.8M in Q1 2026 from $19.3M in Q1 2025, reflecting expanded clinical programs and headcount growth to support public company operations.
MD&A: Cash Flow verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.
Partner
Trade AVLN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 10, 2026 7:05 PM